Coral Budesonide Coral Budesonide

X

Find Drugs in Development News & Deals for Budesonide

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

EU WC

EU WC

Listed Suppliers

Listed Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

0

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • TABLET, EXTENDED RELEASE;ORAL - 9MG
  • AEROSOL, FOAM;RECTAL - 2MG/ACTUATION
  • SPRAY, METERED;NASAL - 0.032MG/SPRAY
  • SUSPENSION;INHALATION - 0.25MG/2ML
  • SUSPENSION;INHALATION - 0.5MG/2ML
  • SUSPENSION;INHALATION - 1MG/2ML
  • CAPSULE, DELAYED RELEASE;ORAL - 6MG
  • CAPSULE, DELAYED RELEASE;ORAL - 9MG
  • CAPSULE, DELAYED RELEASE;ORAL - 3MG
  • AEROSOL, METERED;INHALATION - 0.08MG/INH;0.0045MG/INH
  • AEROSOL, METERED;INHALATION - 0.16MG/INH;0.0045MG/INH

Details:

Kinpeygo (budesonide), a modified-release capsule, Glucocorticoid receptor agonist, has been approved for primary IgA nephropathy.


Lead Product(s): Budesonide

Therapeutic Area: Nephrology Product Name: Kinpeygo

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 30, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Nefecon is an oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity, indicated for IgA nephropathy.


Lead Product(s): Budesonide

Therapeutic Area: Nephrology Product Name: Nefecon

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Nefegan (budesonide) is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. it is approved for the treatment of primary IgA nephropathy.


Lead Product(s): Budesonide

Therapeutic Area: Nephrology Product Name: Nefegan

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 19, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Mankind Pharma will distribute AstraZeneca's anti-asthma inhaled corticosteroid drug Symbicort, (budesonide/formoterol) approved to treat asthma and COPD, in India.


Lead Product(s): Budesonide,Formoterol Fumarate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Symbicort

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Mankind Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 13, 2024